MedTrace Logo

Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices

NCT01613443 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-03-12

No results posted yet for this study

Summary

Concentration determinations of anticoagulants require plasma instead of whole blood, and results are not immediately available to clinicians. Monitoring anticoagulants concentration along with bedside methods may provide an alternative guide for administration of the NOAC.

The purpose of this investigation is to compare bedside coagulation assays in whole blood with plasma concentrations of the new oral anticoagulants (NOAC) in patients treated with therapeutic dosis of NOAC.

Conditions

  • Effect of NOAC on POCT

Sponsors & Collaborators

  • Cardioangiologisches Centrum Bethanien

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-05-31
Completion
2013-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613443 on ClinicalTrials.gov